Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;

University Hospital Basel

Status: Completed

Conditions: Complication of Extracorporeal Circulation; Complication of Coronary Artery Bypass Graft

Treatments: Procedure: use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation

Study type: Observational

Funder types: Other

Identifiers

NCT03612388

2018-00926 ch18Reuthebuch3;

Details and patient eligibility

About

Combined use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).

Enrollment: 211 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• CABG using MPS® or Cardioplexol ®

Exclusion criteria

• use of other colloid solution than Cardioplexol ® or MPS®
• other inventions than CABG
• myocardial infarction <7 days before CABG
• patients denial of data use

Trial design

211 participants in 2 patient groups

cardioplegia with MPS® (Myocardial protection system)

Description:

cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation

Treatment:

Procedure: use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation

cardioplegia with Cardioplexol ®

Description:

cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)